{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00234",
  "@type" : "Drug",
  "clinicalPharmacology" : "Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders.",
  "description" : "Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.",
  "identifier" : "drugbank:DB00234",
  "legalStatus" : [ "Investigational", "Approved" ],
  "mechanismOfAction" : "Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake <i>in vitro</i> to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low <i>in vivo</i> and <i>in vitro</i> affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.",
  "name" : "Reboxetine",
  "nonProprietaryName" : [ "S)-Reboxetine", "Esreboxetine", "Reboxetine", "SID11114256", "(S" ],
  "proprietaryName" : "Davedax",
  "sameAs" : "http://www.drugbank.ca/drugs/DB00234",
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00234.html"
}